Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling

Background and Purpose Heart failure is associated with an impaired NO–soluble guanylyl cyclase (sGC)–cGMP pathway and its augmentation is thought to be beneficial for its therapy. We hypothesized that stimulation of sGC by the sGC stimulator riociguat prevents pathological cardiac remodelling and h...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of pharmacology Vol. 179; no. 11; pp. 2430 - 2442
Main Authors:	Rüdebusch, Julia, Benkner, Alexander, Nath, Neetika, Fleuch, Lina, Kaderali, Lars, Grube, Karina, Klingel, Karin, Eckstein, Gertrud, Meitinger, Thomas, Fielitz, Jens, Felix, Stephan B.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.06.2022
Subjects:	Animals Aorta Body weight Cell culture Cell survival cGMP signalling Collagen Congestive heart failure Cyclic GMP Cyclic GMP - metabolism Echocardiography Ejection fraction Fibroblasts Fibrosis Gene expression Guanylate cyclase Heart failure Heart Failure - pathology Hypertrophy Mice Mice, Inbred C57BL Myocytes Pyrazoles Pyrimidines riociguat RNA sequencing Signal transduction soluble GC Soluble Guanylyl Cyclase Surgery TAC Transcriptomes Ventricle Ventricular Remodeling RNA sequencing heart failure soluble GC TAC cGMP signalling riociguat
ISSN:	0007-1188, 1476-5381, 1476-5381
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!